J Breast Cancer.  2013 Mar;16(1):12-15.

Eribulin for Advanced Breast Cancer: A Drug Evaluation

• Shablak A

Abstract

Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.

Keyword

Breast neoplasms; Eribulin; Microtubule inhibitor

MeSH Terms

Breast
Breast Neoplasms
Drug Evaluation
Ethers, Cyclic
Furans
Humans
Ketones
Macrolides
Microtubules
Ethers, Cyclic
Furans
Ketones
Macrolides

Reference

1. Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod. 2009. 72:507–515.

2. Kingston DG. Cragg GM, Kingston DG, Newman DJ, editors. Taxol and its analogs. Anticancer Agents from Natural Products. 2005. 2nd ed. Boca Raton: CRC Press;123–135.

3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979. 277:665–667.

4. Hirata Y, Ohya S. Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem. 1986. 58:701–710.

5. Pettit GR, Herald CL, Boyd MR, Leet JE, Dufresne C, Doubek DL, et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem. 1991. 34:3339–3340.

6. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem. 1991. 266:15882–15889.

7. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005. 4:1086–1095.

8. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther. 1992. 55:31–51.

9. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001. 61:1013–1021.

10. Zheng W, Seletsky BM, Palme MH, Lydon PJ, Singer LA, Chase CE, et al. Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett. 2004. 14:5551–5554.

11. Seletsky BM, Wang Y, Hawkins LD, Palme MH, Habgood GJ, DiPietro LV, et al. Structurally simplified macrolactone analogues of halichondrin B. Bioorg Med Chem Lett. 2004. 14:5547–5550.

12. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009. 15:4207–4212.

13. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009. 15:4213–4219.

14. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010. 28:3922–3928.

15. Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012. 23:1441–1448.

16. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009. 27:2954–2961.

17. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011. 377:914–923.

18. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010. 10:160–163.

19. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012. 7:574–578.

20. Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011. 12:1045–1052.

21. Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, et al. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer. 2012. 118:2403–2410.

22. Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs. 2012. 30:1203–1207.

23. Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, LeBlanc M, et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs. 2011. 29:352–359.

24. de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol. 2012. 23:1241–1249.

25. U.S. Food and Drug Administration on HALAVEN™ (eribulin mesylate) Injection. Accessed January 4th, 2013. U.S. Food and Drug Administration;http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf.

26. Final appraisal determination on Eribulin for the treatment of locally advanced or metastatic breast cancer. Accessed January 4th, 2013. National Institute for Health and Clinical Excellence;http://www.nice.org.uk/nicemedia/live/13238/57079/57079.pdf.